

Claims:

[Claim 1]. An antigen-binding molecule, optionally isolated, which is capable of binding to CD47, comprising: in extracellular region 1.

2. The antigen-binding molecule according to claim 1, wherein the antigen-binding molecule is capable of binding to the V-type Ig-like domain of CD47.

3. The antigen-binding molecule according to claim 1 or claim 2, wherein the antigen-binding molecule is capable of binding to a polypeptide comprising or consisting of the amino acid sequence shown in SEQ ID NO:9.

4. The antigen-binding molecule according to any one of claims 1 to 3, wherein the antigen-binding molecule is capable of inhibiting interaction between CD47 and SIRP α .

5. The antigen-binding molecule according to any one of claims 1 to 4, wherein the antigen-binding molecule is capable of increasing phagocytosis of CD47-expressing cells.

6. The antigen-binding molecule according to any one of claims 1 to 5, wherein the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:21.

7. The antigen-binding molecule according to any one of claims 1 to 6, wherein the antigen-binding molecule comprises an antigen-binding domain capable of binding to CD47 which comprises:

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:169

HC-CDR2 having the amino acid sequence of SEQ ID NO:170

HC-CDR3 having the amino acid sequence of SEQ ID NO:26,

or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:171

LC-CDR2 having the amino acid sequence of SEQ ID NO:172

LC-CDR3 having the amino acid sequence of SEQ ID NO:173;

or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.

8. The antigen-binding molecule according to any one of claims 1 to 7, wherein the antigen-binding molecule comprises:

(a)

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:24

~~HC-CDR2 having the amino acid sequence of SEQ ID NO:25
HC-CDR3 having the amino acid sequence of SEQ ID NO:26,
or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or
HC-CDR3 are substituted with another amino acid; and~~

~~(ii) a light chain variable (VL) region incorporating the following CDRs:~~

~~LC-CDR1 having the amino acid sequence of SEQ ID NO:32~~

~~LC-CDR2 having the amino acid sequence of SEQ ID NO:33~~

~~LC-CDR3 having the amino acid sequence of SEQ ID NO:34;~~

~~or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or~~

~~LC-CDR3 are substituted with another amino acid;~~

~~or~~

~~(b)~~

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:137

HC-CDR2 having the amino acid sequence of SEQ ID NO:138

HC-CDR3 having the amino acid sequence of SEQ ID NO:26;

~~or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1,~~

~~HC-CDR2, or HC-CDR3 are substituted with another amino acid; and~~

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:32

LC-CDR2 having the amino acid sequence of SEQ ID NO:33

LC-CDR3 having the amino acid sequence of SEQ ID NO:34;

~~or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or~~

~~LC-CDR3 are substituted with another amino acid;~~

~~or~~

~~(c)~~

~~(i) a heavy chain variable (VH) region incorporating the following CDRs:~~

~~HC-CDR1 having the amino acid sequence of SEQ ID NO:24~~

~~HC-CDR2 having the amino acid sequence of SEQ ID NO:25~~

~~HC-CDR3 having the amino acid sequence of SEQ ID NO:26;~~

~~or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1,~~

~~HC-CDR2, or HC-CDR3 are substituted with another amino acid; and~~

~~(ii) a light chain variable (VL) region incorporating the following CDRs:~~

~~LC-CDR1 having the amino acid sequence of SEQ ID NO:139~~

~~LC-CDR2 having the amino acid sequence of SEQ ID NO:141~~

~~LC-CDR3 having the amino acid sequence of SEQ ID NO:34;~~

~~or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-~~

~~CDR2 or LC-CDR3 are substituted with another amino acid;~~

~~or~~

~~(d)~~

~~(i) a heavy chain variable (VH) region incorporating the following CDRs:~~

~~HC-CDR1 having the amino acid sequence of SEQ ID NO:137~~

		HC-CDR2 having the amino acid sequence of SEQ ID NO:138
		HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
		or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
5		(ii) a light chain variable (VL) region incorporating the following CDRs:
		LC-CDR1 having the amino acid sequence of SEQ ID NO:139
		LC-CDR2 having the amino acid sequence of SEQ ID NO:141
		LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
		or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
10	or	
	(e)	
		(i) a heavy chain variable (VH) region incorporating the following CDRs:
		HC-CDR1 having the amino acid sequence of SEQ ID NO:24
15		HC-CDR2 having the amino acid sequence of SEQ ID NO:25
		HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
		or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
		(ii) a light chain variable (VL) region incorporating the following CDRs:
20		LC-CDR1 having the amino acid sequence of SEQ ID NO:140
		LC-CDR2 having the amino acid sequence of SEQ ID NO:141
		LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
		or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
25	or	
	(f)	
		(i) a heavy chain variable (VH) region incorporating the following CDRs:
		HC-CDR1 having the amino acid sequence of SEQ ID NO:137
		HC-CDR2 having the amino acid sequence of SEQ ID NO:138
30		HC-CDR3 having the amino acid sequence of SEQ ID NO:26;
		or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and
		(ii) a light chain variable (VL) region incorporating the following CDRs:
		LC-CDR1 having the amino acid sequence of SEQ ID NO:140
35		LC-CDR2 having the amino acid sequence of SEQ ID NO:141
		LC-CDR3 having the amino acid sequence of SEQ ID NO:34;
		or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;
	or	
40	(g)	
		(i) a heavy chain variable (VH) region incorporating the following CDRs:
		HC-CDR1 having the amino acid sequence of SEQ ID NO:137

~~HC-CDR2 having the amino acid sequence of SEQ ID NO:138~~
~~HC-CDR3 having the amino acid sequence of SEQ ID NO:26;~~
~~or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and~~
(ii) ~~a light chain variable (VL) region incorporating the following CDRs:~~
~~LC-CDR1 having the amino acid sequence of SEQ ID NO:32~~
~~LC-CDR2 having the amino acid sequence of SEQ ID NO:141~~
~~LC-CDR3 having the amino acid sequence of SEQ ID NO:34;~~
~~or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid;~~

or

~~(h)~~

~~(i) a heavy chain variable (VH) region incorporating the following CDRs:~~
~~HC-CDR1 having the amino acid sequence of SEQ ID NO:137~~
~~HC-CDR2 having the amino acid sequence of SEQ ID NO:138~~
~~HC-CDR3 having the amino acid sequence of SEQ ID NO:26;~~
~~or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and~~
~~(ii) a light chain variable (VL) region incorporating the following CDRs:~~
~~LC-CDR1 having the amino acid sequence of SEQ ID NO:32~~
~~LC-CDR2 having the amino acid sequence of SEQ ID NO:33~~
~~LC-CDR3 having the amino acid sequence of SEQ ID NO:142;~~
~~or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.~~

~~9. The antigen-binding molecule according to any one of claims 1 to 8, wherein the antigen-binding molecule comprises:~~

~~(a)~~

~~(i) a heavy chain variable (VH) region incorporating the following CDRs:~~
~~HC-CDR1 having the amino acid sequence of SEQ ID NO:24~~
~~HC-CDR2 having the amino acid sequence of SEQ ID NO:25~~
~~HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and~~
~~(ii) a light chain variable (VL) region incorporating the following CDRs:~~
~~LC-CDR1 having the amino acid sequence of SEQ ID NO:32~~
~~LC-CDR2 having the amino acid sequence of SEQ ID NO:33~~
~~LC-CDR3 having the amino acid sequence of SEQ ID NO:34;~~

or

~~(b)~~

~~(i) a heavy chain variable (VH) region incorporating the following CDRs:~~
~~HC-CDR1 having the amino acid sequence of SEQ ID NO:137~~
~~HC-CDR2 having the amino acid sequence of SEQ ID NO:138~~
~~HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and~~

~~(ii) a light chain variable (VL) region incorporating the following CDRs:~~
~~LC-CDR1 having the amino acid sequence of SEQ ID NO:32~~
~~LC-CDR2 having the amino acid sequence of SEQ ID NO:33~~
~~LC-CDR3 having the amino acid sequence of SEQ ID NO:34;~~

5 or
(c)

(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
10 HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;

15 or
(d)

(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
20 HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:139
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;

25 or
(e)

(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:24
HC-CDR2 having the amino acid sequence of SEQ ID NO:25
30 HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140
LC-CDR2 having the amino acid sequence of SEQ ID NO:141
LC-CDR3 having the amino acid sequence of SEQ ID NO:34;

35 or
(f)

(i) a heavy chain variable (VH) region incorporating the following CDRs:
HC-CDR1 having the amino acid sequence of SEQ ID NO:137
HC-CDR2 having the amino acid sequence of SEQ ID NO:138
40 HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:140

LC-CDR2 having the amino acid sequence of SEQ ID NO:141

LC-CDR3 having the amino acid sequence of SEQ ID NO:34;

or

(g)

5 (i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:137

HC-CDR2 having the amino acid sequence of SEQ ID NO:138

HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

10 LC-CDR1 having the amino acid sequence of SEQ ID NO:32

LC-CDR2 having the amino acid sequence of SEQ ID NO:141

LC-CDR3 having the amino acid sequence of SEQ ID NO:34;

or

(h)

15 (i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:137

HC-CDR2 having the amino acid sequence of SEQ ID NO:138

HC-CDR3 having the amino acid sequence of SEQ ID NO:26; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

20 LC-CDR1 having the amino acid sequence of SEQ ID NO:32

LC-CDR2 having the amino acid sequence of SEQ ID NO:33

LC-CDR3 having the amino acid sequence of SEQ ID NO:142.

25 **[Claim 142]**. The antigen-binding molecule according to ~~any one of claims 1 to 9~~, wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:23, 39, ~~178~~, 127, 129, 130, 131 or 132; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:31, 44, ~~179~~, 128, 133, 134, 135 or 136.

30 **[Claim 143]**. The antigen-binding molecule according to ~~any one of claims 1 to 10~~, wherein the antigen-binding molecule comprises:

(i) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:23; and

35 a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:31;

or

(ii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:39; and

40 a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:44;

or

~~(iii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:178; and~~
~~a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:179;~~

5 or

(~~iii~~iv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:127; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;

10 or

(iv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:129; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;

15 or

(~~vi~~) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:130; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;

20 or

(~~vii~~) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;

25 or

(~~viii~~) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:128;

30 or

(~~viii~~x) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;

35 or

(~~ix~~) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and
a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:133;

40 or

(~~x~~i) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:131; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;

or

(xii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:134;

or

(xiii) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:135;

or

(xiv) a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:132; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:136.

~~12. The antigen-binding molecule according to any one of claims 1 to 5, wherein the antigen-binding molecule is capable of binding to a peptide or polypeptide comprising or consisting of the amino acid sequence of SEQ ID NO:22.~~

~~13. The antigen-binding molecule according to any one of claims 1 to 5 or 12, wherein the antigen-binding molecule comprises:~~

~~(i) a heavy chain variable (VH) region incorporating the following CDRs:~~

~~HC-CDR1 having the amino acid sequence of SEQ ID NO:50~~

~~HC-CDR2 having the amino acid sequence of SEQ ID NO:51~~

~~HC-CDR3 having the amino acid sequence of SEQ ID NO:52;~~

~~or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and~~

~~(ii) a light chain variable (VL) region incorporating the following CDRs:~~

~~LC-CDR1 having the amino acid sequence of SEQ ID NO:58~~

~~LC-CDR2 having the amino acid sequence of SEQ ID NO:59~~

~~LC-CDR3 having the amino acid sequence of SEQ ID NO:60;~~

~~or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.~~

~~14. The antigen-binding molecule according to any one of claims 1 to 5, 12 or 13, wherein the antigen-binding molecule comprises:~~

~~(i) a heavy chain variable (VH) region incorporating the following CDRs:~~

~~HC-CDR1 having the amino acid sequence of SEQ ID NO:50~~

~~HC-CDR2 having the amino acid sequence of SEQ ID NO:51~~

HC-CDR3 having the amino acid sequence of SEQ ID NO:52; and
(ii) a light chain variable (VL) region incorporating the following CDRs:
LC-CDR1 having the amino acid sequence of SEQ ID NO:58
LC-CDR2 having the amino acid sequence of SEQ ID NO:59
LC-CDR3 having the amino acid sequence of SEQ ID NO:60.

15. The antigen-binding molecule according to any one of claims 1 to 5 or 12 to 14, wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:49; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:57.

16. The antigen-binding molecule according to any one of claims 1 to 5 or 12, wherein the antigen-binding molecule comprises:

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:66

HC-CDR2 having the amino acid sequence of SEQ ID NO:67

HC-CDR3 having the amino acid sequence of SEQ ID NO:68;

or a variant thereof in which one or two or three amino acids in one or more of HC-CDR1, HC-CDR2, or HC-CDR3 are substituted with another amino acid; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:74

LC-CDR2 having the amino acid sequence of SEQ ID NO:75

LC-CDR3 having the amino acid sequence of SEQ ID NO:76;

or a variant thereof in which one or two or three amino acids in one or more of LC-CDR1, LC-CDR2 or LC-CDR3 are substituted with another amino acid.

17. The antigen-binding molecule according to any one of claims 1 to 5, 12 or 16, wherein the antigen-binding molecule comprises:

(i) a heavy chain variable (VH) region incorporating the following CDRs:

HC-CDR1 having the amino acid sequence of SEQ ID NO:66

HC-CDR2 having the amino acid sequence of SEQ ID NO:67

HC-CDR3 having the amino acid sequence of SEQ ID NO:68; and

(ii) a light chain variable (VL) region incorporating the following CDRs:

LC-CDR1 having the amino acid sequence of SEQ ID NO:74

LC-CDR2 having the amino acid sequence of SEQ ID NO:75

LC-CDR3 having the amino acid sequence of SEQ ID NO:76.

18. The antigen-binding molecule according to any one of claims 1 to 5, 12, 16 or 17, wherein the antigen-binding molecule comprises:

a VH region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:65; and

a VL region comprising an amino acid sequence having at least 70% sequence identity to the amino acid sequence of SEQ ID NO:73.

19. An antigen-binding molecule, optionally isolated, comprising (i) an antigen-binding molecule according to any one of claims 1 to 18, and (ii) an antigen-binding molecule capable of binding to an antigen other than CD47.

20. The antigen-binding molecule according to any one of claims 1 to 19, wherein the antigen-binding molecule is capable of binding to cells expressing CD47 at the cell surface.

[Claim 214]. The antigen-binding molecule according to any one of claims 1 to 20, wherein the antigen-binding molecule is capable of inhibiting interaction between CD47 and SIRPα.

[Claim 225]. The antigen-binding molecule according to any one of claims 1 to 21, wherein the antigen-binding molecule is a multispecific antigen-binding molecule, and further comprises an antigen-binding domain specific for a target antigen other than capable of increasing phagocytosis of CD47-expressing cells.

23. A chimeric antigen receptor (CAR) comprising an antigen-binding molecule according to any one of claims 1 to 22.

24. A nucleic acid, or a plurality of nucleic acids, optionally isolated, encoding an antigen-binding molecule according to any one of claims 1 to 22 or a CAR according to claim 23.

25. An expression vector, or a plurality of expression vectors, comprising a nucleic acid or a plurality of nucleic acids according to claim 24.

26. A cell comprising an antigen-binding molecule according to any one of claims 1 to 22, a CAR according to claim 23, a nucleic acid or a plurality of nucleic acids according to claim 24, or an expression vector or a plurality of expression vectors according to claim 25.

27. A method comprising culturing a cell comprising a nucleic acid or a plurality of nucleic acids according to claim 24, or an expression vector or a plurality of expression vectors according to claim 25, under conditions suitable for expression of the antigen-binding molecule or CAR from the nucleic acid(s) or expression vector(s).

28. A composition comprising an antigen-binding molecule according to any one of claims 1 to 22, a CAR according to claim 23, a nucleic acid or a plurality of nucleic acids according to claim 24, an expression vector or a plurality of expression vectors according to claim 25, or a cell according to claim 26.

29. An antigen-binding molecule according to any one of claims 1 to 22, a CAR according to claim 23, a nucleic acid or a plurality of nucleic acids according to claim 24, an expression vector or a plurality of

~~expression vectors according to claim 25, a cell according to claim 26, or a composition according to claim 28 for use in a method of medical treatment or prophylaxis.~~

30. ~~An antigen-binding molecule according to any one of claims 1 to 22, a CAR according to claim 23, a nucleic acid or a plurality of nucleic acids according to claim 24, an expression vector or a plurality of expression vectors according to claim 25, a cell according to claim 26, or a composition according to claim 28, for use in a method of treatment or prevention of a cancer.~~

31. ~~Use of an antigen-binding molecule according to any one of claims 1 to 22, a CAR according to claim 23, a nucleic acid or a plurality of nucleic acids according to claim 24, an expression vector or a plurality of expression vectors according to claim 25, a cell according to claim 26, or a composition according to claim 28, in the manufacture of a medicament for use in a method of treatment or prevention of a cancer.~~

32. ~~A method of treating or preventing a cancer, comprising administering to a subject a therapeutically or prophylactically effective amount of an antigen-binding molecule according to any one of claims 1 to 22, a CAR according to claim 23, a nucleic acid or a plurality of nucleic acids according to claim 24, an expression vector or a plurality of expression vectors according to claim 25, a cell according to claim 26, or a composition according to claim 28.~~

33. ~~The antigen-binding molecule, nucleic acid or plurality of nucleic acids, expression vector or plurality of expression vectors, cell or composition for use according to claim 30, the use according to claim 31 or the method according to claim 32, wherein the cancer is selected from: a hematologic malignancy, a myeloid hematologic malignancy, a lymphoblastic hematologic malignancy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, brain cancer, glioblastoma, ovarian cancer, breast cancer, colon cancer, liver cancer, hepatocellular carcinoma, prostate cancer, lung cancer, Non-small Cell Lung Cancer (NSCLC), skin cancer and melanoma.~~

34. ~~A method for increasing phagocytosis of CD47-expressing cells, comprising contacting CD47-expressing cells with an antigen-binding molecule according to any one of claims 1 to 22.~~

35. ~~An *in vitro* complex, optionally isolated, comprising an antigen-binding molecule according to any one of claims 1 to 22 bound to CD47.~~

36. ~~A method comprising contacting a sample containing, or suspected to contain, CD47 with an antigen-binding molecule according to any one of claims 1 to 22, and detecting the formation of a complex of the antigen-binding molecule with CD47.~~

37. ~~— A method of selecting or stratifying a subject for treatment with a CD47-targeted agent, the method comprising contacting, *in vitro*, a sample from the subject with an antigen-binding molecule according to any one of claims 1 to 22 and detecting the formation of a complex of the antigen-binding molecule with CD47.~~

38. ~~Use of an antigen-binding molecule according to any one of claims 1 to 22 as an *in vitro* or *in vivo* diagnostic or prognostic agent.~~

39. ~~Use of an antigen-binding molecule according to any one of claims 1 to 22 in a method for detecting, localizing or imaging a cancer, optionally wherein the cancer is selected from: a hematologic malignancy, a myeloid hematologic malignancy, a lymphoblastic hematologic malignancy, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), bladder cancer, brain cancer, glioblastoma, ovarian cancer, breast cancer, colon cancer, liver cancer, hepatocellular carcinoma, prostate cancer, lung cancer, Non-small Cell Lung Cancer (NSCLC), skin cancer and melanoma.~~